<DOC>
	<DOCNO>NCT03011021</DOCNO>
	<brief_summary>The purpose study investigate safety therapeutic effect ex-vivo expand umbilical cord blood regulatory T cell adjunct Liraglutide autoimmune diabetes .</brief_summary>
	<brief_title>Safety Efficacy Umbilical Cord Blood Regulatory T Cells Plus Liraglutide Autoimmune Diabetes</brief_title>
	<detailed_description>Autoimmune Diabetes Mellitus ( AIDM ) subtype diabetes mellitus cause autoimmune destruction beta cell islet , include Type 1 diabetes Latent Autoimmune Diabetes Adults ( LADA ) . Insulin use routine therapy AIDM alleviate hyperglycemic status , yet effectively prevent progress destruction beta cell preserve function . Regulatory T cell expand umbilical cord blood ( UCB-Treg ) ex-vivo show strong capacity control immune response autoimmune disease , offer hopeful therapeutic way AIDM . Glucagon-like peptide ( GLP-1 ) analog Liraglutide test large-scale clinical trial prove various benefit beta cell glucolipid metabolism Type 2 diabetes obesity patient . However , clinical application AIDM well-defined far . The aim study investigate potential use Liraglutide UCB-Treg infusion AIDM examine safety efficacy new therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes accord ADA criterion &lt; 3 year . Age≥ 18 year . Positive least one antiislet autoantibody : GADA , IA2A , ZnT8A Fasting postprandial plasma Cpeptide 100 pmol/L Written inform consent patient family representative . History family history medullary thyroid carcinoma MEN 2 syndrome ; History chronic acute pancreatitis ; Allergic liraglutide component Victoza® ; Hepatic abnormality ( transaminase &gt; 2 time normal ) ; Renal impairment ( serum creatinine &gt; 133 umol/L ) ; Cardiovascular disease ( hypertension , coronary heart disease , etc . ) ; Presence anemia ( Hb ≤100g/L ) , leukopenia ( &lt; 3.5×109/L ) ; Presence disorder coagulation anticoagulation , thrombocytopenia ( platelet &lt; 100×109/L ) ; Presence acute metabolic disorder ; In case acute ketone acidosis , blood ketone 0.3mmol/L pH low 7.30 ; Presence kind chronic infection immune deficiency , include hepatitis B , hepatitis C , HIV , syphilis tuberculosis , etc . ; Chronic use systemic glucocorticoid immunosuppressive agent 3 month ; Any history malignancy ; Female patient pregnant breastfeeding ; female unwilling use reliable effective form contraception 2 year recruitment ; Presence infectious disease , include active skin infection , flu , fever , upper low respiratory tract infection ; wish participate study keep infection control least 1 week receive Treg product infusion ; Any medical condition , opinion investigator , interfere safe participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Umbilical Cord Blood Regulatory T Lymphocyte</keyword>
	<keyword>Liraglutide</keyword>
</DOC>